University:
Western Sydney University
Course:
MEDI 2003 | Clinical Sciences 2
Academic year:

2024
Views:

251

Pages:

2
Author:

Mariam A. A.

MHC ANTI-TUMOR AGENTS Crizotinib: Uses: ALL, lymphoblastic lymphoma Side Effects: clotting, bleeding, gingivitis, stomatitis, conjunctivitis, cough, rash, constipation, headache, fatigue, insomnia, weight gain, bone marrow suppression, neutropenia, thrombocytopenia, anemia, hypertension, pulmonary embolism, edema Hydroxyzine: Uses: polycythemia vera, past cure, sickle cell anemia Low dose Thalidomide: Component of thalidomide Binds to cereblon Selectively degrades IKZF1, IKZF3 Side Effects: neutropenia, thrombocytopenia, anemia, constipation, peripheral neuropathy, fatigue, insomnia Angiogenesis: Anti-tumor effects Oncogenesis Other agents inhibiting invasion and metastasis In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Migrastatics should target ultimate effector mechanisms to avoid resistance Extracellular stimuli ECM-cell signal transduction Intracellular pathways Small RHO GTPases Integrins Others mall RHO GTPases: Rho Effectors Contractility activators (rock, MACK, and others) Essential mechanisms Actomyosin contractility Migrastatics intervention zone Rac1, Cdc42, and others Actin polymerization regulators (wasp, link, coilin, formin, and Actin Polymerization Invasion Candidate drugs: • Drugs Targeting Actin Polymerization and Function Signaling driving cell mobility is highly redundant • Drugs Destabilizing Actin Cytoskeleton Inhibition of *Drugs Stabilizing Actin Cytoskeleton • Drugs Targeting Contractility resistance • Tropomyosin Inhibitors • Myosin Inhibitors • MLCK Inhibitors itimate effecto • ROCK Inhibitors • Drugs Targeting lon Transport Proteins Trends in Cance